Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
about
Adjuvant chemotherapy for resected early-stage non-small cell lung cancerRole of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new dataPost-operative radiation therapyMediastinal lymph node dissection versus mediastinal lymph node sampling for early stage non-small cell lung cancer: a systematic review and meta-analysisSurgery in 2013 and beyondNeoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancerSystemic and targeted therapies for early-stage lung cancerTowards optimal pathologic staging of resectable non-small cell lung cancerCan microRNAs improve the management of lung cancer patients? A clinician's perspective2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer50 Years of progress in the systemic therapy of non-small cell lung cancerNew TNM classification: achievements and hurdlesPooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.Prognostic value of epidermal growth factor receptor mutations in resected non-small cell lung cancer: a systematic review with meta-analysisProgress of Postoperative Adjuvant Chemotherapy in Stage I Non-small Cell Lung CancerThe Lake Wobegon effect: are all cancer patients above average?International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinomaThe expression of four genes as a prognostic classifier for stage I lung adenocarcinoma in 12 independent cohortsOnline survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancerPrognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancerPrognostic value of microRNA expression in operable non-small cell lung cancer patientsTimely initiation of chemotherapy: a systematic literature review of six priority cancers - results and recommendations for clinical practice.Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer.Improving survival of patients with locally advanced non-small-cell cancer remains a challenge: comment to PROCLAIM.Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer.Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer.Exploiting the noise: improving biomarkers with ensembles of data analysis methodologies.A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancerERCC1 isoform expression and DNA repair in non-small-cell lung cancer.Treatment Outcomes in Stage I Lung Cancer: A Comparison of Surgery and Stereotactic Body Radiation Therapy.[Efficacy and safety of rh-endostatin combined with chemotherapy versus chemotherapy alone for advanced NSCLC: a meta-analysis review].Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study.Feasibility study of adjuvant chemotherapy of S-1 and carboplatin for completely resected non-small cell lung cancer.Pemetrexed plus carboplatin as adjuvant chemotherapy in patients with curative resected non-squamous non-small cell lung cancer.Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.Feasibility of adjuvant chemotherapy with S-1 plus carboplatin followed by single-agent maintenance therapy with S-1 for completely resected non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 1001.Trichostatin A sensitizes cisplatin-resistant A549 cells to apoptosis by up-regulating death-associated protein kinaseAdjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient dataRandomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.
P2860
Q24187439-FF2F2B03-E577-4E63-8D84-39E90AA151A4Q24633254-0A4D8BFA-F0D7-4E03-A663-2B10E4333AD8Q26830376-198296D5-89A4-44A7-A25A-4CB574A2AF5FQ26859343-5CAA6F0F-C321-4251-B9E7-A5F46628E45FQ26863046-6EC74638-D230-425B-A352-7B71649C8A51Q26863742-7834312B-E65D-4182-B4A9-0C1165C78129Q26865490-7BDF62DC-D464-4581-A1BD-7773B849762AQ26991912-33D19A0F-EABB-4FE9-86B6-CCE0A1054C76Q26999304-7EA7467E-05B2-4F2B-97E0-7A07B385853CQ27002509-EF73D039-43A0-431F-8EE2-724F9D8B2EC4Q27014978-4CDDBA62-9DD1-471D-8B04-52FE97A5AE3BQ27022737-1874A767-92E3-4DFA-B600-D60AF7F7E328Q27313799-19DD423F-E930-4F0A-AF7B-52AD684841D1Q27692669-B908E393-2339-4F18-8662-618F65A2DDAEQ28080636-FF5D1605-A4F6-40A7-80F0-3F1CAA26837EQ28303620-5D9B7615-C2DC-4972-B1D2-7EAB132EB5C7Q28303718-7544DC31-FFB8-4897-8512-40CA28FCE250Q28383695-C9E1E950-41CF-458E-AAA9-AF0D0E51C9E8Q28393146-581FB836-2623-4012-96C0-ABA3EA24FC21Q28394974-AE2176B0-BDB7-4E6C-AA84-F93957845978Q28396343-FE2F673D-447C-4D3F-BB7D-4D8A06FFAE52Q30249083-6B25900E-7573-4A31-961A-A2C3D35426E2Q30358684-8F1CFDC0-34D8-4738-8764-249DFE84D83DQ30382413-E79FB7E0-7230-4DA2-9123-099A91940E16Q30416647-D5C5A3C0-D775-4632-BEE2-867635F9CC69Q30497419-88CE7937-9FB0-42EE-BE70-EE9AFB9C3B7EQ30498101-4C6403BE-8F5D-48E5-9E40-4E1EF8843D0AQ30536424-CF0094DD-C6F1-419A-8EE7-1983FA156164Q30539299-4EA24FC0-E9B3-4E3C-8C1F-FABFE729983DQ30580553-0FD4B6B3-42BF-4AE2-9634-9D7FA7C28E78Q30693104-034B0CC8-13BF-4EEC-9451-1CCB803F4891Q33395300-EC90DAE7-0446-4E57-B7D2-A3662E416C6AQ33404434-4F23B366-9B9F-4D18-8B68-B4488A98D4A7Q33408830-8D6AE566-4122-447F-98CF-7A374C3E467DQ33429178-02A5FC8D-2AA9-4733-8D83-B8ECC5F0BC59Q33429478-F04F7D95-BCBF-49DB-9F24-43D840B72B6BQ33437409-AD07C1AC-7564-40E0-92F3-887AB753DA60Q33521840-3D197A17-989F-4884-8F19-61DB761D5E84Q33546241-E61764A4-0A65-47D5-A0AA-E7FBB35F5DC9Q33561943-D94FCE1E-7981-43BD-A84F-5279F016E324
P2860
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
@en
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
@nl
type
label
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
@en
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
@nl
prefLabel
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
@en
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
@nl
P2093
P50
P356
P1476
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
@en
P2093
Ariane Dunant
David Waller
Delphine Aubert
Estelle Rolland
Frances A Shepherd
Giorgio V Scagliotti
Hélène Tribodet
Jean-Pierre Pignon
Keyue Ding
LACE Collaborative Group
P304
P356
10.1200/JCO.2007.13.9030
P407
P577
2008-05-27T00:00:00Z